Clinical experience strongly supports its use for the indications below but we're working with promising preclinical data, not robust human RCTs
2,3 Furthermore, several cardiovascular outcome trials (CVOT) suggest GLP-1 RAs confer a mortality benefit, with significant reductions in major adverse cardiovascular events, all-cause mortality, heart failure severity, and worsening kidney function
Pflugers Archiv-European J Physiol (2017) 469:38596
Ivim Health's study in Obesity Pillars is a concrete differentiator - though you should evaluate other platforms' evidence (or lack thereof) on the same terms
The safety and well-being of our clients are of utmost importance to us
The Peptide Problem: Why Oral GLP-1 Was So Difficult Glucagon-like peptide-1 is a 30-amino-acid incretin hormone secreted by enteroendocrine L-cells in the distal small intestine in response to nutrient ingestion